Mojo ParametersPrice Summary - 04:50 PM on 02-May 
Performance Today
Underperformed Sector by -0.58%
Consecutive Fall
Stock has been losing for the last 7 days and has fallen -10.71% returns in the period
Moving Averages
Venus Remedies is trading lower than 5 day, 20 day, 50 day, 100 day and 200 day moving averages
Falling Investor Participation
Delivery Vol of 12.81 k on 30 Apr has fallen by -10.18% against 5-day avg delivery vol
Stock DNA
Pharmaceuticals & Drugs
Rs 409 Cr (Micro Cap)
15.00
36
0.00%
-0.19
4.47%
0.83
Total ReturnsTotal Returns (Price + Dividend)
Latest dividend: 3 per share ex-dividend date: Sep-23-2013
Risk Adjusted Returns v/s Sensex
Returns Beta
News & Corporate ActionsNews
Venus Remedies Faces Shift in Market Sentiment Despite Strong Financial Performance
Venus Remedies, a microcap in the Pharmaceuticals & Drugs sector, has seen a recent evaluation adjustment reflecting a shift in technical indicators. Despite strong quarterly results, including significant growth in operating profit and net sales, the stock has underperformed against the broader market over the past year.
Read More
Venus Remedies Reports Strong Profit Growth Amid Shift in Technical Trend
Venus Remedies, a microcap in the Pharmaceuticals & Drugs sector, has recently adjusted its evaluation, reflecting a shift in technical trends. The company reported a significant increase in profit before tax and operating profit growth, alongside strong cash reserves and net sales, indicating a positive financial trajectory.
Read More
Venus Remedies Reports Strong Q3 FY24-25 Performance Amid Market Challenges
Venus Remedies, a microcap pharmaceutical company, recently experienced a score adjustment following its third-quarter FY24-25 results, which highlighted strong debt servicing capabilities and significant operating profit growth. Despite facing challenges in the stock market, the company reported a notable increase in net sales and demonstrated healthy long-term growth potential.
Read More Announcements
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
22-Apr-2025 | Source : BSE<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Venus Remedies Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24232CH1989PLC009705</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>0.00</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>NSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. YES</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Neha <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: complianceofficer@venusremedies.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Pawan Chaudhary <br/> Designation: CFO <br/> EmailId: corpsec@venusremedies.com</div> </div> <div> <br/> Date: 22/04/2025<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>
Change In Email Address Of RTA
18-Apr-2025 | Source : BSEChange in email address of RTA.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
17-Apr-2025 | Source : BSEUSFDA grants Qualified Infectious Disease Product Designation to Venus Remedies VRP-034 a Novel Polymyxin B Formulation
Corporate Actions
No Upcoming Board Meetings
Venus Remedies Ltd has declared 30% dividend, ex-date: 23 Sep 13
No Splits history available
No Bonus history available
No Rights history available
Key FactorsQuality key factors
Valuation key factors
Tecnicals key factors
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned ShareholdingShareholding Snapshot : Mar 2025
Shareholding Compare (%holding)
Non Institution
None
Held by 0 Schemes
Held by 5 FIIs (1.34%)
Sunev Pharma Solutions Limited (17.21%)
Pradeep Kumar Jain (2.78%)
46.81%
FinancialQuarterly Results Snapshot (Consolidated) - Dec'24 - YoY
Compare with Peers 
YoY Growth in quarter ended Dec 2024 is 23.32% vs 22.69% in Dec 2023
YoY Growth in quarter ended Dec 2024 is 186.13% vs 108.21% in Dec 2023
Half Yearly Results Snapshot (Consolidated) - Sep'24
Growth in half year ended Sep 2024 is 5.02% vs -7.10% in Sep 2023
Growth in half year ended Sep 2024 is -57.37% vs -9.00% in Sep 2023
Nine Monthly Results Snapshot (Consolidated) - Dec'24
YoY Growth in nine months ended Dec 2024 is 11.48% vs 1.61% in Dec 2023
YoY Growth in nine months ended Dec 2024 is 35.45% vs 15.86% in Dec 2023
Annual Results Snapshot (Consolidated) - Mar'24
YoY Growth in year ended Mar 2024 is 8.27% vs -7.44% in Mar 2023
YoY Growth in year ended Mar 2024 is 7.23% vs -34.79% in Mar 2023
Company CVAbout Venus Remedies Ltd
Company Coordinates
